By Sheri Kasprzak
New York, Dec. 11 - Halozyme Therapeutics, Inc. settled a private placement of stock for $11,068,950.
The company sold 3.385 million shares at $3.27 each to an affiliate of F. Hoffman-La Roche Ltd., Roche Finance Ltd.
Halozyme entered into a licensing agreement with F. Hoffman-La Roche to develop and commercialize rHuPH20, the company's recombinant human hyaluronidase.
Halozyme, based in San Diego, develops recombinant human enzymes to treat infertility, palliative care, drug delivery and oncology treatments.
| Issuer: | Halozyme Therapeutics, Inc.
|
| Issue: | Stock
|
| Amount: | $11,068,950
|
| Shares: | 3.385 million
|
| Price: | $3.27
|
| Warrants: | No
|
| Investor: | Roche Finance Ltd.
|
| Settlement date: | Dec. 5
|
| Stock symbol: | Amex: HTI
|
| Stock price: | $2.85 at close Dec. 5
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
